1 Association of flame retardants, polybrominated diethyl ethers (PBDEs), with vitamin 2 **D** in female subjects 3 Alexandra E. Butler<sup>1\*</sup>, Edwina Brennan<sup>1</sup>, Daniel S. Drage<sup>2,3</sup>, Thozhukat Sathvapalan<sup>4</sup>, 4 5 Stephen L. Atkin<sup>1</sup> 6 <sup>1</sup>School of Medicine, Royal College of Surgeons in Ireland-Medical University of Bahrain, 7 Busaiteen, Bahrain; ebrennan@rcsi.com; satkin@rcsi.com 8 9 <sup>2</sup>School of Geography, Earth and Environmental Sciences, University of Birmingham, 10 Edgbaston, West Midlands, B15 2TT, UK; D.S.Drage@bham.ac.uk 11 12 <sup>3</sup>Queensland Alliance for Environmental Health Sciences, The University of Queensland, 39 13 Kessels Road, Coopers Plains, Qld, 4108, Australia 14 15 <sup>4</sup>Hull York Medical School, University of Hull, UK; thozhukat.sathyapalan@hyms.ac.uk 16 17 Running title: Association of PBDEs with Vitamin D 18 *Key terms:* polybrominated diethyl ethers; PBDE; organic pollutants; vitamin D; cholecalciferol 19 20 Word count: Abstract: 290; Main manuscript: 2,604 Figures and Tables: 3 Figures, 2 Tables 21 22 23 Author emails: Alexandra E. Butler aeb91011@gmail.com; abutler@rcsi.com 24 25 Edwina Brennan ebrennan@rcsi.com 26 Daniel S Drage d.s.drage@bham.ac.uk 27 Thozhukat Sathyapalan Thozhukat.Sathyapalan@hyms.ac.uk 28 Stephen L Atkin satkin@rcsi.com 29 30 31 32 \* Corresponding author: Alexandra E. Butler, Royal College of Surgeons in Ireland Bahrain, Adliva, Kingdom of Bahrain. aeb91011@gmail.com; abutler@rcsi.com 33 Phone: +973 32360292 34 35 36 Funding: No funding was received to perform this study. Conflict of interest: None to disclose. 37 38 39

# 40 Abstract

41	Introduction. A class of flame retardants, polybrominated diethyl ethers (PBDEs), are
42	known endocrine disrupters and may induce the hepatic enzymes CYP24 and CYP3A that
43	promote 25-hydroxylation of vitamin D <sub>3</sub> . Therefore, this study examined the association of
44	PBDEs with vitamin $D_3$ (25(OH) $D_3$ ) and the active 1,25-dihydrovitamin $D_3$ (1,25(OH) <sub>2</sub> $D_3$ ) in
45	a cohort of non-obese women.
46	Methods. 58 female participants (age:31.9±4.6 years; body mass index (BMI):25.7±3.7
47	kg/m <sup>2</sup> ) had seven indicator PBDEs [PBDE28;PBDE47;PBDE99;PBDE100;PBDE153;
48	PBDE154;PBDE183] measured using high resolution gas chromatography, with $\Sigma$ PBDE
49	level calculated. 25(OH)D3 and 1,25(OH)2D3 levels were determined by isotope-dilution
50	liquid chromatography tandem mass spectrometry. Plasma level of calcium/calmodulin-
51	dependent protein kinase type 1 (CaMK1) was measured by Somascan proteomics.
52	Results. In this cohort, vitamin D <sub>3</sub> (25(OH)D <sub>3</sub> ) and 1,25(OH) <sub>2</sub> D <sub>3</sub> levels were 22.9±11.2
53	ng/mL and $0.05\pm0.02$ ng/mL, respectively. Of those, 28 had vitamin D deficiency [25(OH)D <sub>3</sub>
54	level <20 ng/mL (<50nmol/L)]. For the whole group, individual PBDEs (PBDE28;
55	PBDE47;PBDE99;PBDE100;PBDE153;PBDE154;PBDE183) and ΣPBDEs did not correlate
56	with 25(OH)D <sub>3</sub> or its active metabolite 1,25(OH) <sub>2</sub> D <sub>3</sub> nor with BMI.
57	For the subset who were 25(OH)D3 sufficient, negative correlations were found for
58	1,25(OH) <sub>2</sub> D <sub>3</sub> with PBDE153 ( $\rho$ =-0.77;p=0.02) and PBDE100 ( $\rho$ =-0.72;p=0.005). In the
59	subset of women who were 25(OH)D3 deficient, positive correlations were found for
60	1,25(OH) <sub>2</sub> D <sub>3</sub> with PBDE153 ( $\rho$ =0.68;p=0.02) and $\Sigma$ PBDEs ( $\rho$ =0.57;p=0.03). Using
61	sufficient and deficient subset categories, no correlations were seen with 25(OH)D3 nor any
62	of the PBDEs, and PBDEs did not correlate to renal function (estimated glomerular filtration
63	rate, eGFR). 1,25(OH) <sub>2</sub> D <sub>3</sub> was negatively associated with CaMK1 (r= -0.36;p=0.03) as was
64	PBDE153 (r=-0.31;p=0.02).

- 65 **Conclusion.** PBDEs were not associated with 25(OH)D<sub>3</sub>, but PBDE100 and 153 correlated
- 66 with its active 1,25(OH)<sub>2</sub>D<sub>3</sub> metabolite and PBDE153 correlated to the calcium modulator
- 67 CaMKI, suggesting that PBDE effects could either be mediated through vitamin D status or
- 68 that functional inactivation or inhibition of 1,25(OH)<sub>2</sub>D<sub>3</sub> may contribute to the impact of
- 69 vitamin D deficiency.

#### 70 Introduction

71 Polybrominated diethyl ethers (PBDEs) are a group of synthetic chemicals that are used as 72 flame retardants and monitoring data has shown that their concentrations have increased 73 rapidly in both animals and humans, particularly in infants and toddlers; they enter the body 74 through inhalation and ingestion (Linares, Bellés et al. 2015). These chemicals exist as polybrominated formulations (tri, tetra, penta, hexa, hepta formulations for example) that 75 may make up a large proportion of a product weight; for example, 15% of plastic may be 76 77 PBDEs (Linares, Bellés et al. 2015). As they are resistant to degradation, they bioaccumulate 78 (Law, Covaci et al. 2014), though highly brominated PBDEs such as dexa formulations may 79 debrominate to lower brominated congeners that are more toxic (Law, Covaci et al. 2014); 80 however, it is unclear if this happens in the body. Animal studies have suggested that PBDEs 81 are associated with liver toxicity (Shockley, Cora et al. 2020), thyroid toxicity (Li, Gao et al. 2020), neurodevelopmental toxicity (Dorman, Chiu et al. 2018) and impaired sperm motility 82 83 (Li, Gao et al. 2021), but no single congener appears to be more associated with health effects 84 than another. 85 Vitamin D deficiency is associated with differing health conditions including osteoporosis,

86 cancer, cardiovascular disease, autoimmune diseases and increased mortality (Bjelakovic,

87 Gluud et al. 2014, Osorio Landa, Perez Diaz et al. 2020). Vitamin D<sub>3</sub> (cholecalciferol) is the

result of UVB irradiation of 7-dehydrocholesterol; vitamin D<sub>3</sub> is the product of

89 phototransformation of 7-dehydrocholesterol in which, after absorption of UVB, the B ring is

90 broken and the D<sub>3</sub> configuration is thermally driven (Kim, Atigadda et al. 2020). Under high

91 doses of UVB, pre-vitamin D<sub>3</sub> isomerizes to tachysterol or lumisterol that has anti-

92 proliferative, anti-inflammatory and anti-cancer properties (Slominski, Chaiprasongsuk et al.

93 2020). Subsequently, there is hydroxylation of vitamin D to 25(OH)D<sub>3</sub> in the liver (Bikle

94 2014). Subsequently,  $25(OH)D_3$  needs to be converted to 1,25-dihydroxyvitamin  $D_3$ 

95 (1,25(OH)<sub>2</sub>D<sub>3</sub>), its active metabolite that occurs primarily in the kidneys. In addition, there are alternative pathways of vitamin D activation initiated by CYP11A1 that are biologically 96 97 active locally and may contribute systemically (Slominski, Kim et al. 2015, Slominski, Li et 98 al. 2015). PBDEs may induce the cytochrome P450 (CYP) enzymes through activation of both the aryl hydrocarbon dependent and independent pathways (Sanders, Burka et al. 2005), 99 100 and the CYP enzymes mediate vitamin D metabolism (Kasarla, Garikapati et al. 2022). 101 Therefore, PBDEs may be associated with vitamin D levels, despite a report indicating that PBDEs showed little association with vitamin D in pilot whales (Hoydal, Ciesielski et al. 102 103 2016). Therefore, this study was undertaken to look at the association of PBDEs (tri-PBDE28, tetra-PBDE47, penta-PBDE99, penta-PBDE100, hexa-PBDE153, hexa-PBDE154 104 105 and hepta-PBDE183) with 25(OH)D<sub>3</sub> and its active metabolite 1,25(OH)<sub>2</sub>D<sub>3</sub> in a group of 106 non-obese women prior to them undergoing in vitro fertilization (IVF).

107

## 108 Methods

109 Patient recruitment. Subjects were recruited from the Hull IVF Unit, UK, following ethical

110 approval from The Yorkshire and The Humber NRES ethical committee, UK (approval

111 number 02/03/043). Venesection was performed on 58 fasting, non-obese Caucasian women;

samples were taken at 0900 on day 21 of the menstrual cycle prior to IVF downregulation.

113 All participants gave written informed consent.

114

115 Polybrominated diethyl ethers measurement.

116 Samples were analyzed for 7 PBDEs [PBDE28, PBDE47, PBDE99, PBDE100, PBDE153,

117 PBDE154 and PBDE183], as previously described (Drage, Heffernan et al. 2019). Five mL of

serum was aliquoted into a 50 mL polypropylene centrifuge tube. Samples were spiked with 5

119 ng each of internal standards ( ${}^{13}C_{12}$ -labelled PBDEs -28, -47, -99, -100, -153, -154, -183).

120 Samples were vortexed for approximately 1 minute and left to stand for 30 minutes. 6 mL acetonitrile, 3 mL milliQ, 5 g anhydrous MgSO<sub>4</sub> and 1 g NaCl were added along with a ceramic 121 122 homogenizer. Samples were manually shaken for 1 minute prior to centrifuging at 4500 RPM 123 for 8 minutes at 10 °C. The supernatant layer was collected and transferred to a glass tube. The extract was evaporated to near-dryness on a hot plate using a gentle stream of nitrogen and 124 reconstituted in approximately 1 mL hexane. 1 mL >98% concentrated sulfuric acid was added 125 126 and the sample was vortexed for at least 30 seconds. The aqueous and organic layers were left to separate overnight at <4 °C. The supernatant layer was transferred directly onto a silica solid 127 128 phase extraction cartridge (Supelco LC-Si 3mL/500 mg), preconditioned with 6 mL dichloromethane, followed by 6 mL hexane. The sample was allowed to load onto the cartridge 129 gravimetrically. Target compounds were eluted into a glass tube using 6 mL hexane, followed 130 131 by 8 mL dichloromethane at approximately 2 mL/min. The sample was evaporated to neardryness and reconstituted in 100 µL iso-octane containing 2.5 ng <sup>13</sup>C<sub>12</sub>-PCB-141 as a recovery 132 133 standards. After analysis for PBDEs by high resolution gas chromatography coupled with high 134 resolution mass spectrometry (HRGC/HRMS).

135

136 Instrumental Analysis

For PBDE analysis by HRGC/HRMS,a Thermofisher TRACE 1300 gas chomatograph was
coupled to a Thermofisher DFS mass spectrometer. The injector was operated in splitless mode
with separation achieved on an Agilent DB-5ms column (30 m length x 0.25 mm in diameter
x 0.25 μm film thickness). Experiments were conducted in MID mode at 10,000 resolution
(10% valley definition). The inlet, transfer line and source were held at 250 °C, 280 °C and 280
°C respectively. The flow rate was maintained at 1.0 mL/min. Details of acquisition ions for
PBDEs are outlined in (Drage, Heffernan et al. 2019) and quality assurance checks using

144	previously described methods (Wang, Banks et al. 2019). A sum PBDE ( $\sum$ PBDE) variable was
145	calculated by adding together the molar concentrations of the PBDE congeners analyzed.
146	
147	Vitamin D <sub>3</sub> and biochemical parameters.
148	Biochemical and hormonal parameters were measured as previously detailed (Brennan,
149	Kumar et al. 2022). Isotope-dilution liquid chromatography tandem mass spectrometry (LC-
150	MS/MS) was used to determine vitamin D levels (Javed, Papageorgiou et al. 2019), with a
151	25(OH)D <sub>3</sub> cut off of 20ng/mL (50nmol/L) to define vitamin D deficiency.
152	
153	Calcium/calmodulin-dependent protein kinase type 1 (CaMK1) proteomic measurement.
154	Circulating levels of complement pathway proteins were determined by Slow Off-rate
155	Modified Aptamer (SOMA)-scan plasma protein measurement (Somalogic, Boulder, CO,
156	USA), the details of which have been previously reported (Moin, Sathyapalan et al. 2021).
157	Normalization of raw intensities, hybridization, median signal and calibration signal were
158	performed based on the standard samples included on each plate, as previously described
159	(Moin, Sathyapalan et al. 2023).
160	
161	Statistics.
162	No previous studies were available to perform a power analysis, therefore this pilot study was
163	designed according to Birkett and Day (Birkett and Day 1994). Data are presented as mean $\pm$
164	SD. PBDE levels, hormone concentrations, and metabolic markers were assessed for
165	normality and Independent T or Mann-Whitney U tests were used to compare
166	means/medians, as appropriate. Potential associations were examined using Spearman's rank

167 order correlations or Pearson's product moment correlations. A p-value of <0.05 was

168 considered to indicate statistical significance. Statistical analysis was carried out using169 Jamovi (version 2.0.0).

170

- 172 Whole cohort analysis. Demographic and biochemical data for this cohort are shown in Table
- 173 1. The participants had a mean age of 31.9±4.6 years and a mean body mass index (BMI) of
- 174 25.7±3.7 kg/m<sup>2</sup>. Thyroid function and C-reactive protein, as a measure of underlying
- inflammation, were normal. Mean levels of vitamin D<sub>3</sub> (25(OH)D<sub>3</sub>) and 1,25(OH)<sub>2</sub>D<sub>3</sub> were
- 176 22.9±11.2 ng/mL and 0.05±0.02 ng/mL, respectively.
- 177 Of the 58 women recruited, 28 had a 25(OH)D<sub>3</sub> level less than 20 ng/mL (50 nmol/L). Levels
- 178 of PBDEs,  $25(OH)D_3$  and  $1,25(OH)_2D_3$  are shown in Table 1. Those women that had vitamin
- 179 D sufficiency were statistically older by 1.6 years (p<0.01) and had a higher T3 (p<0.002),
- 180 but the TSH levels did not differ. None of the PBDEs differed significantly between
- 181 sufficient and insufficient though PBDE100 and total PBDE were higher in sufficiency, but
- failed to reach significance (p<0.06 and 0.08, respectively). PBDE28, PBDE47, PBDE99,
- 183 PBDE100 and PBDE153 had detection frequencies of 31%, 90%, 64%, 69% and 59%,

184 respectively, whilst PBDE154 and PBDE183 were not detected.

185

186 Whole group correlations. Individual PBDEs (PBDE28, PBDE47, PBDE99, PBDE100,

187 PBDE153, PBDE154 and PBDE183) and ΣPBDEs did not correlate with 25(OH)D<sub>3</sub> or its

- active metabolite  $1,25(OH)_2D_3$  nor with BMI (Table 2).
- 189
- 190 Subset correlations. When the subset of women who were 25(OH)D<sub>3</sub> sufficient (>20 ng/mL;
- 191 >50 nmol/L) were analyzed, strong negative correlations were found for  $1,25(OH)_2D_3$  with
- 192 PBDE153 ( $\rho$ =-0.77;p=0.02) and PBDE100 ( $\rho$ =-0.72;p=0.005) (Figure 1A, B). In the subset

193 of women who were 25(OH)D<sub>3</sub> deficient (<20 ng/mL; <50 nmol/L), strong positive correlations were found for 1,25(OH)<sub>2</sub>D<sub>3</sub> with PBDE153 ( $\rho$ =0.68;p=0.02) and  $\Sigma$ PBDEs 194 195 (p=0.57;p=0.03) (Figure 1C, D). Using sufficient and deficient subset categories, no 196 correlations were seen with 25(OH)D<sub>3</sub> and any of the PBDEs. Using sufficient and deficient subset categories, no correlations were found between eGFR 197 198 and the individual PBDEs nor  $\Sigma$ PBDEs that associated with 1,25(OH)<sub>2</sub>D<sub>3</sub> (data not shown). 199 200 Association with calcium/calmodulin-dependent protein kinase type 1 (CaMK1). 201 To investigate a possible mechanism by which PBDE may affect 1,25(OH)<sub>2</sub>D<sub>3</sub> action, 202 determination of plasma levels of calcium/calmodulin-dependent protein kinase type 1 203 (CaMK1), that may be indicative of 1,25(OH)<sub>2</sub>D<sub>3</sub> action, was subsequently undertaken 204 (Ellison, Dowd et al. 2005). Here, we found that 1,25(OH)<sub>2</sub>D<sub>3</sub> was negatively associated with CaMK1 (r= -0.36, p=0.03), and that PBDE153 was also negatively associated with CaMK1 205 206 (r = -0.31, p = 0.02) (Figure 2).

207

#### 208 Discussion

209 These data show that 7 indicator PBDEs and  $\Sigma$ PBDEs do not appear to be associated with

210 25(OH)D<sub>3</sub> levels. Mechanistically, PBDEs activate CYP3A and CYP3B (Lundgren,

211 Darnerud et al. 2007) that are involved in vitamin D metabolism by converting 25(OH)D<sub>3</sub> to

212 inactive metabolites (Kasarla, Garikapati et al. 2022) and, therefore, it may have been

anticipated that PBDEs would have been associated with vitamin D and perhaps more

associated with vitamin D sufficiency, but this was not seen here. However, in the absence of

- an association of PBDEs with 25(OH)D<sub>3</sub>, the lack of association with 1,25(OH)<sub>2</sub>D<sub>3</sub> for the
- 216 group as a whole was not unexpected. What was surprising was the negative correlation of
- 217 PBDE153 and PBDE100 with 1,25(OH)<sub>2</sub>D<sub>3</sub> in those subjects that were vitamin D sufficient.

This would suggest that the PBDEs are perhaps acting on CYP3, resulting in increased 218 inactivation of 1,25(OH)<sub>2</sub>D<sub>3</sub>, perhaps through CYP promoting 23R- and 24S-mediated 219 220 conversion of 1,25(OH)<sub>2</sub>D<sub>3</sub> into inactive 1a,23R,25(OH)<sub>2</sub>D<sub>3</sub> and 1a,24S,25(OH)<sub>2</sub>D<sub>3</sub> (Kasarla, 221 Garikapati et al. 2022). Conversely, in the subset of women who were 25(OH)D<sub>3</sub> deficient, 222 strong positive correlations were found for  $1,25(OH)_2D_3$  with PBDE153 and  $\Sigma$ PBDE. Both PBDE100 and ΣPBDE were higher in deficiency though not statistically different, but could 223 224 be considered to show a trend. Women with vitamin D sufficiency were older but likely this 225 was not clinically significant, and had a higher T3, but the TSH as a measure of thyroid 226 function did not differ between groups suggesting that whilst statistically different, it was not 227 clinically important. What is well recognized is that production of  $1,25(OH)_2D_3$  occurs in the 228 renal cortex and is enhanced by vitamin D deficiency (Armbrecht, Zenser et al. 1981). 229 Speculatively, PBDE may act through PPAR-y (Tung, Boudreau et al. 2014) and it is known that PPAR may decrease CYP (Bouillon and Bikle 2019) that may reflect in the increase in 230 231 1,25(OH)<sub>2</sub>D<sub>3</sub>. An alternate speculative scenario can be inferred from the fact that, in the 232 presence of vitamin D deficiency in pigs,  $1\alpha$ -hydroxylase, the enzyme responsible for the 233 production of 1,25(OH)<sub>2</sub>D<sub>3</sub>, increases five to ten fold (Engstrom, Horst et al. 1984), so PBDE 234 may be blunting the overall enzymatic response to 1,25(OH)<sub>2</sub>D<sub>3</sub> formation. It is likely that the diverse observations in the vitamin D sufficient and deficient groups cancelled each other 235 236 out so that, overall, there appeared not to be an association of PBDE with 1,25(OH)<sub>2</sub>D<sub>3</sub>. 237 Specific studies are required to determine the underlying mechanisms for the observations 238 reported for PBDE on vitamin D sufficient and deficient subjects, but currently the literature 239 is scant to predict the underlying mechanism(s). Given that there was no correlation with 240 eGFR as a marker of renal function, these effects on 1.25(OH)<sub>2</sub>D<sub>3</sub> are likely not mediated 241 through a nephrotoxic mechanism. In addition, extrarenal tissues may also convert 25(OH)D<sub>3</sub> 242 to 1,25(OH)<sub>2</sub>D<sub>3</sub> although, notably, activation in renal and non-kidney tissues is regulated

differently with macrophage production of 1,25(OH)<sub>2</sub>D<sub>3</sub> through the type 2 interferon 243 response (Adams, Rafison et al. 2014); it has been shown that PBDE47 can modulate the 244 245 macrophage immune response (Longo, Longo et al. 2021), suggesting that this could be 246 another mechanism by which the PBDEs may modulate 1,25(OH)<sub>2</sub>D<sub>3</sub> effects *in vivo*. 247 Clinically, this observation of the association of PBDEs with 1,25(OH)<sub>2</sub>D<sub>3</sub> may be important 248 and requires validation with a larger series and a focus on the underlying mechanism of 249 action to determine if there is causality. Vitamin D deficiency affects 50% of the world, 250 reaching over 70% in countries such as Pakistan (Siddigee, Bhattacharjee et al. 2021) and is 251 associated with differing health conditions including osteoporosis, cancer, cardiovascular 252 disease, autoimmune diseases, diabetes and increased mortality (Bjelakovic, Gluud et al. 253 2014, Osorio Landa, Perez Diaz et al. 2020). The PBDE global burden may not be distributed equally with less industrialized regions showing accelerated growth of manufacturing 254 255 industries in their booming economies, leading to higher consumption with inappropriate 256 waste management practices causing increased PBDE concentrations in the environment and 257 in human tissues in some Asian and African countries (Abbasi, Li et al. 2019), but it is 258 unclear if the global PBDE burden maps to global vitamin D deficiency on a country by 259 country basis.

260 To investigate a possible mechanism by which PBDE may affect 1,25(OH)<sub>2</sub>D<sub>3</sub> action,

determination of plasma levels of CaMK1, that may be indicative of 1,25(OH)<sub>2</sub>D<sub>3</sub> action, was

undertaken. 1,25(OH)<sub>2</sub>D<sub>3</sub> exerts rapid actions at the cell membrane that include increasing

263 intracellular calcium levels through CaMKIV (Ellison, Dowd et al. 2005). CaMKIV signaling

stimulates vitamin D receptor (VDR)-mediated transcription by increasing phosphorylation

levels of VDR and enhancing autonomous steroid receptor coactivator (SRC) activity,

resulting in higher 1,25(OH)<sub>2</sub>D<sub>3</sub>-dependent interaction between VDR and SRC coactivators

267 (Ellison, Dowd et al. 2005). In addition, there are alternative nuclear receptors for the

hydroxy-derivatives of vitamin D<sub>3</sub> including retinoic acid-related orphan receptors, the aryl 268 hydrocarbon receptor and liver X receptors (Slominski, Kim et al. 2014, Slominski, 269 270 Chaiprasongsuk et al. 2020, Slominski, Kim et al. 2021) that may be affected by PBDEs. 271 The consensus sequences for phosphorylation by CaMKI and CaMKIV are similar, and hence these kinases phosphorylate the same substrates (Hook and Means 2001, Beghi, 272 273 Furmanik et al. 2022). Here, we found that 1,25(OH)<sub>2</sub>D<sub>3</sub> was negatively associated with 274 CaMK1, and that PBDE153 was also negatively associated with CaMK1, suggesting that 275 increasing levels of PBDE153 may be acting at the level of calcium modulation through 276 calmodulin-dependent kinases (Figure 3). Strengths of this study include the state-of-the-art measurement of the PBDEs and vitamin D 277 (25(OH)D<sub>3</sub> and 1,25(OH)<sub>2</sub>D<sub>3</sub>). Limitations of the study include the small numbers of subjects 278 279 and that they were all Caucasian females, so these findings may not be generalizable to male subjects or those of differing ethnicities. The selection of participants from women without 280 281 obesity prior to undergoing in vitro fertilization may have introduced a selection bias to the 282 present study as their lifestyle is focused upon optimizing their potential fertility. The low 283 numbers compounded by the PBDE detection rate may have resulted in a type 2 statistical 284 error (false negative); however, this study would allow the determination of power for a larger study focusing on vitamin D deficiency. One of the major limitations in the 285 interpretation of the results is that there are very few studies in humans on this subject; 286 287 therefore, the inference of the results is derived from animal studies in differing species that 288 may not be directly comparable to man. In conclusion, our findings show that PBDEs were not associated with 25(OH)D<sub>3</sub>, but 289 290 PBDE100 and 153 correlated with its active 1,25(OH)<sub>2</sub>D<sub>3</sub> metabolite and PBDE153 291 correlated to CaMKI for calcium modulation, suggesting that PBDE effects could either be

292 mediated through vitamin D status or that functional inactivation or inhibition of

293 1,25(OH)<sub>2</sub>D<sub>3</sub> may contribute to the impact of vitamin D deficiency.

- 294
- 295

## 296 DECLARATIONS

- 297 *Ethics approval and consent to participate:* All procedures performed in studies involving
- 298 human participants were in accordance with the ethical standards of The Yorkshire and The
- Humber NRES ethical committee, UK (approval number 02/03/043) and with the 1964
- 300 Helsinki declaration and its later amendments or comparable ethical standards.
- 301 *Consent for publication:* All authors gave their consent for publication.
- 302 *Availability of data and materials:* All the data for this study will be made available upon303 reasonable request to the corresponding author.
- 304 *Competing interests:* No authors have any conflict of interest or competing interests to declare.
- 305 *Funding:* No funding was received to perform this study.
- 306 *Authors' contributions:*
- 307 AEB analyzed the data and wrote the manuscript. TS supervised clinical studies and edited the

308 manuscript. DSD performed the PBDE analyses. SLA and EB contributed to study design, data

- interpretation and the writing of the manuscript. All authors reviewed and approved the final
- 310 version of the manuscript. Alexandra E Butler is the guarantor of this work.
- 311 *Acknowledgments:* not applicable
- 312
- 313

# 314 References

- 315 Abbasi, G., L. Li and K. Breivik (2019). "Global Historical Stocks and Emissions of
- **316** PBDEs." <u>Environ Sci Technol</u> **53**(11): 6330-6340.
- 317 Adams, J. S., B. Rafison, S. Witzel, R. E. Reyes, A. Shieh, R. Chun, K. Zavala, M. Hewison
- and P. T. Liu (2014). "Regulation of the extrarenal CYP27B1-hydroxylase." J Steroid
- 319 <u>Biochem Mol Biol</u> 144 Pt A: 22-27.
- 320 Armbrecht, H. J., T. V. Zenser and B. B. Davis (1981). "Conversion of 25-hydroxyvitamin
- 321 D3 to 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 in renal slices from the
   322 rat." Endocrinology 109(1): 218-222.
- 323 Beghi, S., M. Furmanik, A. M. G. Jaminon, R. Veltrop, N. Rapp, K. Wichapong, E. Bidar, A.
- 324 Buschini and L. J. Schurgers (2022). "Calcium Signalling in Heart and Vessels: Role of
- 325 Calmodulin and Downstream Calmodulin-Dependent Protein Kinases." <u>International Journal</u>
- 326 of Molecular Sciences 23.
- Bikle, D. D. (2014). "Vitamin D metabolism, mechanism of action, and clinical applications."
  Chem Biol 21(3): 319-329.
- 329 Birkett, M. A. and S. J. Day (1994). "Internal pilot studies for estimating sample size."
- 330 <u>Statistics in Medicine</u> **13**(23-24): 2455-2463.
- 331 Bjelakovic, G., L. L. Gluud, D. Nikolova, K. Whitfield, J. Wetterslev, R. G. Simonetti, M.
- Bjelakovic and C. Gluud (2014). "Vitamin D supplementation for prevention of mortality in
  adults." Cochrane Database Syst Rev(1): Cd007470.
- Bouillon, R. and D. Bikle (2019). "Vitamin D Metabolism Revised: Fall of Dogmas." J Bone
   <u>Miner Res</u> 34(11): 1985-1992.
- 336 Brennan, E., N. Kumar, D. S. Drage, T. K. Cunningham, T. Sathyapalan, J. F. Mueller and S.
- 337 L. Atkin (2022). "A case-control study of polychlorinated biphenyl association with
- 338 metabolic and hormonal outcomes in polycystic ovary syndrome." J Environ Sci Health C
- 339 <u>Toxicol Carcinog</u> **40**(1): 86-105.
- 340 Dorman, D. C., W. Chiu, B. F. Hales, R. Hauser, K. J. Johnson, E. Mantus, S. Martel, K. A.
- 341 Robinson, A. A. Rooney, R. Rudel, S. Sathyanarayana, S. L. Schantz and K. M. Waters
- 342 (2018). "Polybrominated diphenyl ether (PBDE) neurotoxicity: a systematic review and
- 343 meta-analysis of animal evidence." J Toxicol Environ Health B Crit Rev 21(4): 269-289.
- 344 Drage, D. S., A. L. Heffernan, T. K. Cunningham, L. L. Aylward, J. F. Mueller, T.
- 345 Sathyapalan and S. L. Atkin (2019). "Serum measures of hexabromocyclododecane
- (HBCDD) and polybrominated diphenyl ethers (PBDEs) in reproductive-aged women in theUnited Kingdom." Environ Res 177: 108631.
- Ellison, T. I., D. R. Dowd and P. N. MacDonald (2005). "Calmodulin-dependent kinase IV
- 349 stimulates vitamin D receptor-mediated transcription." <u>Mol Endocrinol</u> 19(9): 2309-2319.
- 350 Engstrom, G. W., R. L. Horst, T. A. Reinhardt and E. T. Littledike (1984). "25-
- Hydroxyvitamin D 1 alpha- and 24-hydroxylase activities in pig kidney homogenates: effect
- 352 of vitamin D deficiency." <u>J Nutr</u> **114**(1): 119-126.
- Hook, S. S. and A. R. Means (2001). "Ca(2+)/CaM-dependent kinases: from activation to
- 354 function." <u>Annu Rev Pharmacol Toxicol</u> **41**: 471-505.
- 355 Hoydal, K. S., T. M. Ciesielski, A. Borrell, A. Wasik, R. J. Letcher, M. Dam and B. M.
- 356 Jenssen (2016). "Relationships between concentrations of selected organohalogen
- 357 contaminants and thyroid hormones and vitamins A, E and D in Faroese pilot whales."
- **358** <u>Environ Res</u> **148**: 386-400.
- 359 Javed, Z., M. Papageorgiou, H. Deshmukh, E. S. Kilpatrick, V. Mann, L. Corless, G.
- 360 Abouda, A. S. Rigby, S. L. Atkin and T. Sathyapalan (2019). "A Randomized, Controlled
- 361 Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver
- 362 Markers in Women with Polycystic Ovary Syndrome." <u>Nutrients</u> 11(1).

- 363 Kasarla, S. S., V. Garikapati, Y. Kumar and S. Dodoala (2022). "Interplay of Vitamin D and
- 364 CYP3A4 Polymorphisms in Endocrine Disorders and Cancer." <u>Endocrinol Metab (Seoul)</u>
   365 37(3): 392-407.
- 366 Kim, T. K., V. Atigadda, P. Brzeminski, A. Fabisiak, E. K. Y. Tang, R. C. Tuckey and A. T.
- 367 Slominski (2020). "Detection of 7-Dehydrocholesterol and Vitamin D3 Derivatives in
  368 Honey." Molecules 25(11).
- 369 Law, R. J., A. Covaci, S. Harrad, D. Herzke, M. A. Abdallah, K. Fernie, L. M. Toms and H.
- Takigami (2014). "Levels and trends of PBDEs and HBCDs in the global environment: status
  at the end of 2012." Environ Int 65: 147-158.
- 372 Li, P., H. Gao, L. Dong, L. Liu, G. Zhou, C. Luo, Z. Tian, T. Xia, A. Wang and S. Zhang
- 373 (2020). "Perinatal low-dose PBDE-47 exposure hampered thyroglobulin turnover and
- 374 induced thyroid cell apoptosis by triggering ER stress and lysosomal destabilization
- 375 contributing to thyroid toxicity in adult female rats." <u>J Hazard Mater</u> **392**: 122265.
- 376 Li, X., H. Gao, P. Li, W. Chen, S. Tang, L. Liu, G. Zhou, T. Xia, A. Wang and S. Zhang
- 377 (2021). "Impaired sperm quantity and motility in adult rats following gestational and
- lactational exposure to environmentally relevant levels of PBDE-47: A potential role of
  thyroid hormones disruption." Environ Pollut 268(Pt A): 115773.
- Linares, V., M. Bellés and J. L. Domingo (2015). "Human exposure to PBDE and critical
   application of health hereads." Arch Toxical 80(2): 225-256
- evaluation of health hazards." <u>Arch Toxicol</u> **89**(3): 335-356.
- 382 Longo, V., A. Longo, G. Adamo, A. Fiannaca, S. Picciotto, L. La Paglia, D. Romancino, M.
- 383 La Rosa, A. Urso, F. Cibella, A. Bongiovanni and P. Colombo (2021). "2,2'4,4'-
- 384 Tetrabromodiphenyl Ether (PBDE-47) Modulates the Intracellular miRNA Profile, sEV
- 385 Biogenesis and Their miRNA Cargo Exacerbating the LPS-Induced Pro-Inflammatory
- Response in THP-1 Macrophages." <u>Front Immunol</u> **12**: 664534.
- 387 Lundgren, M., P. O. Darnerud, Y. Molin, H. Lilienthal, J. Blomberg and N. G. Ilbäck (2007).
- "Coxsackievirus B3 infection and PBDE exposure causes organ-specific effects on CYP-gene
   expression in the mouse." <u>Toxicology</u> 242(1-3): 91-99.
- 390 Moin, A. S. M., T. Sathyapalan, A. E. Butler and S. L. Atkin (2021). "Vitamin D association
- with coagulation factors in polycystic ovary syndrome is dependent upon body mass index." J
   <u>Transl Med</u> 19(1): 239.
- 393 Moin, A. S. M., T. Sathyapalan, A. E. Butler and S. L. Atkin (2023). "Coagulation factor
- dysregulation in polycystic ovary syndrome is an epiphenomenon of obesity." <u>Clin</u>
   Endocrinol (Oxf).
- 396 Osorio Landa, H. K., I. Perez Diaz, S. D. C. Laguna Barcenas, J. M. Lopez Navarro, M. F.
- 397 Abella Roa, M. Corral Orozco, J. P. Mancilla Ortega, D. A. Martinez Duarte, S. I. Morales
- 398 Montalvo, S. Muzquiz Aguirre and E. Sanchez Landa (2020). "Association of serum vitamin
- 399 D levels with chronic disease and mortality." <u>Nutr Hosp</u>.
- 400 Sanders, J. M., L. T. Burka, C. S. Smith, W. Black, R. James and M. L. Cunningham (2005).
- "Differential expression of CYP1A, 2B, and 3A genes in the F344 rat following exposure to a
- 402 polybrominated diphenyl ether mixture or individual components." <u>Toxicol Sci</u> 88(1): 127403 133.
- 404 Shockley, K. R., M. C. Cora, D. E. Malarkey, D. Jackson-Humbles, M. Vallant, B. J. Collins,
- 405 E. Mutlu, V. G. Robinson, S. Waidyanatha, A. Zmarowski, N. Machesky, J. Richey, S.
- 406 Harbo, E. Cheng, K. Patton, B. Sparrow and J. K. Dunnick (2020). "Comparative toxicity and
- 407 liver transcriptomics of legacy and emerging brominated flame retardants following 5-day
  408 exposure in the rat." <u>Toxicol Lett</u> 332: 222-234.
- 409 Siddiqee, M. H., B. Bhattacharjee, U. R. Siddiqi and M. MeshbahurRahman (2021). "High
- 410 prevalence of vitamin D deficiency among the South Asian adults: a systematic review and
- 411 meta-analysis." <u>BMC Public Health</u> **21**(1): 1823.

- 412 Slominski, A. T., A. Chaiprasongsuk, Z. Janjetovic, T. K. Kim, J. Stefan, R. M. Slominski,
- 413 V. S. Hanumanthu, C. Raman, S. Qayyum, Y. Song, Y. Song, U. Panich, D. K. Crossman, M.
- 414 Athar, M. F. Holick, A. M. Jetten, M. A. Zmijewski, J. Zmijewski and R. C. Tuckey (2020).
- 415 "Photoprotective Properties of Vitamin D and Lumisterol Hydroxyderivatives." <u>Cell</u>
- 416 <u>Biochem Biophys</u> **78**(2): 165-180.
- 417 Slominski, A. T., T. K. Kim, W. Li, A. Postlethwaite, E. W. Tieu, E. K. Y. Tang and R. C.
- 418 Tuckey (2015). "Detection of novel CYP11A1-derived secosteroids in the human epidermis
- and serum and pig adrenal gland." <u>Sci Rep</u> 5: 14875.
- 420 Slominski, A. T., T. K. Kim, S. Qayyum, Y. Song, Z. Janjetovic, A. S. W. Oak, R. M.
- 421 Slominski, C. Raman, J. Stefan, C. A. Mier-Aguilar, V. Atigadda, D. K. Crossman, A. Golub,
- 422 Y. Bilokin, E. K. Y. Tang, J. Y. Chen, R. C. Tuckey, A. M. Jetten and Y. Song (2021).
- 423 "Vitamin D and lumisterol derivatives can act on liver X receptors (LXRs)." <u>Sci Rep</u> 11(1):
  424 8002.
- 425 Slominski, A. T., T. K. Kim, Y. Takeda, Z. Janjetovic, A. A. Brozyna, C. Skobowiat, J.
- 426 Wang, A. Postlethwaite, W. Li, R. C. Tuckey and A. M. Jetten (2014). "RORα and ROR γ
- 427 are expressed in human skin and serve as receptors for endogenously produced noncalcemic
- 428 20-hydroxy- and 20,23-dihydroxyvitamin D." <u>Faseb j</u> 28(7): 2775-2789.
- 429 Slominski, A. T., W. Li, T. K. Kim, I. Semak, J. Wang, J. K. Zjawiony and R. C. Tuckey
- 430 (2015). "Novel activities of CYP11A1 and their potential physiological significance." J
- 431 <u>Steroid Biochem Mol Biol</u> 151: 25-37.
- 432 Tung, E. W., A. Boudreau, M. G. Wade and E. Atlas (2014). "Induction of adipocyte
- differentiation by polybrominated diphenyl ethers (PBDEs) in 3T3-L1 cells." <u>PLoS One</u> 9(4):
  e94583.
- 435 Wang, X., A. P. W. Banks, C. He, D. S. Drage, C. L. Gallen, Y. Li, Q. Li, P. K. Thai and J. F.
- 436 Mueller (2019). "Polycyclic aromatic hydrocarbons, polychlorinated biphenyls and legacy
- 437 and current pesticides in indoor environment in Australia occurrence, sources and exposure
- 438 risks." <u>Sci Total Environ</u> 693: 133588.
- 439
- 440
- 441

Table 1. Demographics of the 58 female subjects in the population studied. Data are presented for the whole cohort as well as for the vitamin D
 sufficient and deficient subgroups.

	Female subjects (n=58)		Vitamin D sufficient female subjects (n=30)		Vitamin D deficient female subjects (n=28)		P-value Vitamin D sufficient vs deficient
	Mean	SD	Mean	SD	Mean	SD	
Age (years)	31.9	4.6	33.4	4.6	30.3	4.2	0.01
BMI (kg/m <sup>2</sup> )	25.7	3.7	26.3	3.5	25	3.9	0.17
CRP (mg/L)	2.6	2.5	2.4	2.5	2.8	2.5	0.63
TSH (mU/L)	2.4	2.2	2	0.9	2.8	3	0.22
Free-T3 (pmol/L)	4.8	0.7	5.1	0.7	4.5	0.6	0.002
Free-T4 (pmol/L)	11.3	1.8	11.5	1.9	11.2	1.7	0.53
25(OH)D <sub>3</sub> (ng/mL)	23	11.2	29.9	7.5	11.4	4.9	<0.0001
1,25(OH) <sub>2</sub> D <sub>3</sub> (ng/mL)	0.05	0.02	0.05	0.02	0.04	0.02	0.02
PBDE28 (ng/g Lipid)	0.15	0.05	0.15	0.05	0.15	0.06	0.99
PBDE47 (ng/g Lipid)	0.7	0.69	0.59	0.49	0.85	0.87	0.18
PBDE99 (ng/g Lipid)	0.26	0.17	0.23	0.1	0.28	0.21	0.33
PBDE100 (ng/g Lipid)	0.36	0.37	0.26	0.24	0.48	0.47	0.06
PBDE153 (ng/g Lipid)	2.33	2.26	1.79	0.76	2.87	3.05	0.17

PBDE154 (ng/g Lipid)	<0.3		<0.3		<0.3		
PBDE183 (ng/g Lipid)	<0.4		<0.4		<0.4		
∑PBDEs (ng/g Lipid)	2.45	2.65	1.88	1.62	3.11	3.39	0.08
eGFR (mL/min/1.73m <sup>2</sup> )	92.3	14.8	84.6	7.4	86.1	6.9	0.48

445 BMI: Body mass index; CRP: C reactive protein; TSH: thyroid stimulating hormone; Free-T3: Free Triiodothyronine; Free-T4: Free Thyroxine;

446 PBDE: polybrominated diethyl ether; eGFR: estimated glomerular filtration rate.

## 

# **Table 2.** Spearman's rho (p) correlations between PBDEs, 25(OH)D<sub>3</sub>, 1,25(OH)<sub>2</sub>D<sub>3</sub> and BMI.

	PBDE28	PBDE47	PBDE99	PBDE100	PBDE153	ΣPBDEs
25(OH)D <sub>3</sub>	-0.104	-0.122	-0.153	-0.216	-0.025	-0.275
(ng/mL)	(0.70)	(0.43)	(0.41)	(0.23)	(0.89)	(0.06)
1,25(OH) <sub>2</sub> D <sub>3</sub>	0.092	-0.298	-0.252	-0.35	0.079	-0.061
(ng/mL)	(0.75)	(0.09)	(0.26)	(0.10)	(0.74)	(0.72)
DMI	0.011	0.037	0.114	0.253	-0.032	-0.018
DIVII	(0.96)	(0.79)	(0.50)	(0.12)	(0.86)	(0.89)

454 PBDEs: polybrominated diethyl ethers; BMI: Body mass index

456 457	Figure legends					
458	Figure 1. Correlations of 1,25(OH) <sub>2</sub> D <sub>3</sub> with PBDEs in female subjects categorized according to vitamin D sufficiency or deficiency. A cut off					
459	value for 25(OH)D <sub>3</sub> of 20ng/mL (50nmol/L) was used, above which subjects were categorized as vitamin D sufficient and below which subjects					
460	were classified as deficient. Negative correlations of vitamin D sufficient women were seen for 1,25(OH) <sub>2</sub> D3 with PBDE153 (A) and PBDE100					
461 462	(B). Positive correlations of vitamin D deficient women were seen for $1,25(OH)_2D_3$ with PBDE153 (C) and $\Sigma$ PBDEs (D).					
463	Figure 2. Correlations of calcium/calmodulin-dependent protein kinase type 1 (CaMK1) with 1,25(OH) <sub>2</sub> D <sub>3</sub> (A) and polybrominated diethyl ether					
464	153 (PBDE153) (B).					
465	RFU: relative fluorescent units					
466						
467	Figure 3. A schematic to illustrate the effect of 1,25(OH) <sub>2</sub> D <sub>3</sub> on cell signaling pathways, specifically upon calcium/calmodulin-dependent					
468	protein kinases (CaMKs). The active form of vitamin D, 1,25(OH)2D3, binds to the vitamin D receptor (VDR) through which it exerts its					
469	effects. The VDR affects multiple downstream cell signaling pathways, including cAMP, PIP3, PKA, PKC, MAPKs, and CaMKs.					
470	VDR, vitamin D receptor; cAMP, cyclic adenosine monophosphate; PIP3, phosphatidylinositol (3,4,5)-trisphosphate; PKA, protein kinase A; PKC,					
471	protein kinase C; MAPKs, mitogen activated protein kinases; CaMKs, calcium/calmodulin-dependent protein kinases.					
472 173						
474						

Figure 1. Correlations of 1,25(OH)<sub>2</sub>D<sub>3</sub> with PBDEs in female subjects categorized according to vitamin D sufficiency or deficiency. A cut off
value for 25(OH)D<sub>3</sub> of 20ng/mL (50nmol/L) was used, above which subjects were categorized as vitamin D sufficient and below which subjects
were classified as deficient. Negative correlations of vitamin D sufficient women were seen for 1,25(OH)<sub>2</sub>D<sub>3</sub> with PBDE153 (A) and PBDE100
(B). Positive correlations of vitamin D deficient women were seen for 1,25(OH)<sub>2</sub>D<sub>3</sub> with PBDE153 (C) and ΣPBDEs (D).



485 Figure 2. Correlations of calcium/calmodulin-dependent protein kinase type 1 (CaMK1) with 1,25(OH)<sub>2</sub>D<sub>3</sub> (A) and polybrominated diethyl ether
 486 153 (PBDE153) (B).

*RFU: relative fluorescent units* 





**491** Figure 3. A schematic to illustrate the effect of  $1,25(OH)_2D_3$  on cell signaling pathways, specifically upon calcium/calmodulin-dependent

- 492 protein kinases (CaMKs). The active form of vitamin D, 1,25(OH)<sub>2</sub>D<sub>3</sub>, binds to the vitamin D receptor (VDR) through which it exerts its
  493 effects. The VDR affects multiple downstream cell signaling pathways, including cAMP, PIP3, PKA, PKC, MAPKs, and CaMKs.
- 493 effects. The VDR affects multiple downstream cell signaling pathways, including CAMP, PIP3, PKA, PKC, MAPKs, and CaMKs. 494 *VDR*, vitamin D receptor; cAMP, cyclic adenosine monophosphate; PIP3, phosphatidylinositol (3,4,5)-trisphosphate; PKA, protein kinase A; PKC,
- 494 *For the analysis of the second state of t*
- 496
- 497

